Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
GSK's Cash to Debt is ranked lower than
80% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. GSK: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
GSK' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.46 Max: N/A
Current: 0.24
Interest Coverage 2.33
GSK's Interest Coverage is ranked lower than
89% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. GSK: 2.33 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 2.48  Med: 10.1 Max: 22.2
Current: 2.33
2.48
22.2
F-Score: 4
Z-Score: 1.12
M-Score: -2.65
WACC vs ROIC
9.36%
4.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.58
GSK's Operating margin (%) is ranked lower than
55% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. GSK: 6.58 )
Ranked among companies with meaningful Operating margin (%) only.
GSK' s Operating margin (%) Range Over the Past 10 Years
Min: 6.58  Med: 28.78 Max: 43.15
Current: 6.58
6.58
43.15
Net-margin (%) 1.13
GSK's Net-margin (%) is ranked lower than
69% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. GSK: 1.13 )
Ranked among companies with meaningful Net-margin (%) only.
GSK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.13  Med: 19.26 Max: 35.2
Current: 1.13
1.13
35.2
ROE (%) 10.70
GSK's ROE (%) is ranked higher than
64% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. GSK: 10.70 )
Ranked among companies with meaningful ROE (%) only.
GSK' s ROE (%) Range Over the Past 10 Years
Min: 10.7  Med: 61.62 Max: 179.63
Current: 10.7
10.7
179.63
ROA (%) 0.54
GSK's ROA (%) is ranked lower than
65% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. GSK: 0.54 )
Ranked among companies with meaningful ROA (%) only.
GSK' s ROA (%) Range Over the Past 10 Years
Min: 0.54  Med: 13.04 Max: 20.43
Current: 0.54
0.54
20.43
ROC (Joel Greenblatt) (%) 17.74
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. GSK: 17.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GSK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.74  Med: 84.46 Max: 120.14
Current: 17.74
17.74
120.14
Revenue Growth (3Y)(%) -2.60
GSK's Revenue Growth (3Y)(%) is ranked lower than
73% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. GSK: -2.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GSK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.2  Med: 4.8 Max: 15.3
Current: -2.6
-4.2
15.3
EBITDA Growth (3Y)(%) 14.30
GSK's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. GSK: 14.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GSK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18  Med: 7.6 Max: 17.4
Current: 14.3
-18
17.4
EPS Growth (3Y)(%) 24.10
GSK's EPS Growth (3Y)(%) is ranked higher than
75% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. GSK: 24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GSK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.3  Med: 5 Max: 51.3
Current: 24.1
-30.3
51.3
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

GSK Guru Trades in Q4 2015

Steven Cohen 87,100 sh (New)
Kahn Brothers 84,600 sh (+47.13%)
Murray Stahl 26,348 sh (+2.43%)
NWQ Managers 469,830 sh (+1.68%)
John Rogers 1,476,976 sh (+1.29%)
Joel Greenblatt 51,973 sh (+1.01%)
Ken Fisher 11,531,673 sh (+0.03%)
Barrow, Hanley, Mewhinney & Strauss 249,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
Tweedy Browne 133,124 sh (-0.25%)
PRIMECAP Management 4,250,285 sh (-0.35%)
HOTCHKIS & WILEY 12,102,919 sh (-2.40%)
Pioneer Investments 551,520 sh (-5.26%)
Diamond Hill Capital 160,031 sh (-5.52%)
Charles Brandes 4,303,030 sh (-7.92%)
Jeff Auxier 136,032 sh (-8.40%)
Sarah Ketterer 518,275 sh (-14.52%)
Dodge & Cox 112,782 sh (-44.42%)
Jim Simons 176,400 sh (-87.67%)
» More
Q1 2016

GSK Guru Trades in Q1 2016

Jeremy Grantham 79,900 sh (New)
Lee Ainslie 28,520 sh (New)
Jim Simons 480,600 sh (+172.45%)
Kahn Brothers 131,950 sh (+55.97%)
John Rogers 1,582,913 sh (+7.17%)
NWQ Managers 498,115 sh (+6.02%)
Charles Brandes 4,474,409 sh (+3.98%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (+1.12%)
Ken Fisher 11,657,855 sh (+1.09%)
First Eagle Investment 1 sh (unchged)
Pioneer Investments 551,520 sh (unchged)
Francis Chou 18,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 51,331 sh (-1.24%)
Murray Stahl 25,973 sh (-1.42%)
Diamond Hill Capital 151,307 sh (-5.45%)
Tweedy Browne 116,070 sh (-12.81%)
Sarah Ketterer 450,405 sh (-13.10%)
Jeff Auxier 111,282 sh (-18.19%)
HOTCHKIS & WILEY 8,915,323 sh (-26.34%)
Dodge & Cox 81,262 sh (-27.95%)
PRIMECAP Management 1,116,885 sh (-73.72%)
» More
Q2 2016

GSK Guru Trades in Q2 2016

NWQ Managers 2,075,187 sh (+316.61%)
Kahn Brothers 380,335 sh (+188.24%)
Jeremy Grantham 154,880 sh (+93.84%)
Jim Simons 510,800 sh (+6.28%)
John Rogers 1,607,697 sh (+1.57%)
Ken Fisher 11,730,875 sh (+0.63%)
Tweedy Browne 116,491 sh (+0.36%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Francis Chou 18,000 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 1,115,985 sh (-0.08%)
Jeff Auxier 110,732 sh (-0.49%)
Pioneer Investments 543,125 sh (-1.52%)
HOTCHKIS & WILEY 8,439,389 sh (-5.34%)
Charles Brandes 4,224,506 sh (-5.59%)
Sarah Ketterer 329,801 sh (-26.78%)
Dodge & Cox 44,262 sh (-45.53%)
Joel Greenblatt 25,857 sh (-49.63%)
» More
Q3 2016

GSK Guru Trades in Q3 2016

John Hussman 50,000 sh (New)
Jeremy Grantham 1,563,336 sh (+909.39%)
Jim Simons 930,000 sh (+82.07%)
Kahn Brothers 632,040 sh (+66.18%)
NWQ Managers 2,658,155 sh (+28.09%)
Ken Fisher 11,861,172 sh (+1.11%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
John Rogers 1,607,697 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Pioneer Investments 542,025 sh (-0.20%)
PRIMECAP Management 1,109,085 sh (-0.62%)
Sarah Ketterer 327,419 sh (-0.72%)
Tweedy Browne 114,844 sh (-1.41%)
Joel Greenblatt 25,284 sh (-2.22%)
HOTCHKIS & WILEY 8,150,402 sh (-3.42%)
Jeff Auxier 105,772 sh (-4.48%)
Dodge & Cox 41,962 sh (-5.20%)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (-6.59%)
Charles Brandes 3,525,668 sh (-16.54%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:BMY, NYSE:ABBV, NYSE:SNY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, NYSE:NVS, OTCPK:OTSKF, NYSE:MRK, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, OTCPK:MAYNF, NAS:HCM » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three areas - pharmaceutical, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Guru Investment Theses on GlaxoSmithKline PLC

Ariel Funds Comments on GlaxoSmithKline plc - Sep 28, 2016

In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair.

From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Kahn Brothers Adds to 4 Holdings in 3rd Quarter Largest acquisition is in GlaxoSmithKline
Kahn Brothers (Trades, Portfolio) added to four holdings in its portfolio in the third quarter. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Strong Revenue Points to Gains at GlaxoSmithKline Business purchases could be key revenue generators
In the biotech arena, there are few names that attract as much attention as GlaxoSmithKline PLC (NYSE:GSK), which closed at $43.42 on Sept. 23, 2016 (down by 0.37 percent from the previous close). The stock has gyrated in a 52-week range between $37.24 and $45.58, which indicates that valuations are currently at the bullish end of the spectrum. Read more...
Ariel Funds Comments on GlaxoSmithKline plc Guru stock highlight
In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair. Read more...
Kahn Brothers Adds to BP, GlaxoSmithKline Stakes Firm founded by Irving Kahn adds to 8 holdings
Legendary investor Irving Kahn, along with his brothers Thomas Graham and Alan Kahn, founded the Kahn Brothers (Trades, Portfolio) Group in 1978, an investment firm that manages more than $800 million in assets. Irving Kahn trained directly with Benjamin Graham and served as his teaching assistant at Columbia Business School. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 244.50
GSK's P/E(ttm) is ranked lower than
96% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. GSK: 244.50 )
Ranked among companies with meaningful P/E(ttm) only.
GSK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.35  Med: 14.72 Max: 99999999.99
Current: 244.5
6.35
99999999.99
Forward P/E 14.53
GSK's Forward P/E is ranked higher than
52% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. GSK: 14.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 244.50
GSK's PE(NRI) is ranked lower than
97% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. GSK: 244.50 )
Ranked among companies with meaningful PE(NRI) only.
GSK' s PE(NRI) Range Over the Past 10 Years
Min: 6.38  Med: 14.65 Max: 284.83
Current: 244.5
6.38
284.83
Price/Owner Earnings (ttm) 16.61
GSK's Price/Owner Earnings (ttm) is ranked higher than
77% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. GSK: 16.61 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GSK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.75  Med: 16.55 Max: 45.91
Current: 16.61
4.75
45.91
P/B 523.93
GSK's P/B is ranked lower than
100% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. GSK: 523.93 )
Ranked among companies with meaningful P/B only.
GSK' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.35 Max: 610.36
Current: 523.93
5.48
610.36
P/S 2.70
GSK's P/S is ranked higher than
52% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. GSK: 2.70 )
Ranked among companies with meaningful P/S only.
GSK' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.8 Max: 4.02
Current: 2.7
1.94
4.02
PFCF 26.24
GSK's PFCF is ranked lower than
58% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. GSK: 26.24 )
Ranked among companies with meaningful PFCF only.
GSK' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 17.01 Max: 135.68
Current: 26.24
8.24
135.68
POCF 14.33
GSK's POCF is ranked higher than
57% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. GSK: 14.33 )
Ranked among companies with meaningful POCF only.
GSK' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.6 Max: 27.31
Current: 14.33
6.61
27.31
EV-to-EBIT 49.93
GSK's EV-to-EBIT is ranked lower than
83% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. GSK: 49.93 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.7 Max: 72.6
Current: 49.93
6.3
72.6
EV-to-EBITDA 27.82
GSK's EV-to-EBITDA is ranked lower than
71% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. GSK: 27.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 35.2
Current: 27.82
5.6
35.2
PEG 32.17
GSK's PEG is ranked lower than
96% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. GSK: 32.17 )
Ranked among companies with meaningful PEG only.
GSK' s PEG Range Over the Past 10 Years
Min: 0.64  Med: 1.64 Max: 41.51
Current: 32.17
0.64
41.51
Shiller P/E 15.32
GSK's Shiller P/E is ranked higher than
90% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.94 vs. GSK: 15.32 )
Ranked among companies with meaningful Shiller P/E only.
GSK' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 14.95 Max: 20
Current: 15.32
11.71
20
Current Ratio 0.97
GSK's Current Ratio is ranked lower than
88% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. GSK: 0.97 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.26 Max: 1.78
Current: 0.97
0.93
1.78
Quick Ratio 0.67
GSK's Quick Ratio is ranked lower than
88% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. GSK: 0.67 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.99 Max: 1.42
Current: 0.67
0.63
1.42
Days Inventory 200.25
GSK's Days Inventory is ranked lower than
83% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. GSK: 200.25 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 183.91 Max: 202.64
Current: 200.25
167.28
202.64
Days Sales Outstanding 99.54
GSK's Days Sales Outstanding is ranked lower than
67% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. GSK: 99.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 71.39 Max: 99.54
Current: 99.54
54.62
99.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.54
GSK's Dividend Yield is ranked higher than
98% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. GSK: 5.54 )
Ranked among companies with meaningful Dividend Yield only.
GSK' s Dividend Yield Range Over the Past 10 Years
Min: 2.79  Med: 5.1 Max: 6.24
Current: 5.54
2.79
6.24
Dividend Payout 13.73
GSK's Dividend Payout is ranked lower than
86% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. GSK: 13.73 )
Ranked among companies with meaningful Dividend Payout only.
GSK' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.69 Max: 13.73
Current: 13.73
0.14
13.73
Dividend Growth (3y) 0.40
GSK's Dividend Growth (3y) is ranked lower than
65% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. GSK: 0.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GSK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 6.3 Max: 20.8
Current: 0.4
-12.6
20.8
Forward Dividend Yield 4.96
GSK's Forward Dividend Yield is ranked higher than
96% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. GSK: 4.96 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 6.71
GSK's Yield on cost (5-Year) is ranked higher than
94% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. GSK: 6.71 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GSK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.38  Med: 6.18 Max: 7.56
Current: 6.71
3.38
7.56
3-Year Average Share Buyback Ratio 0.20
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. GSK: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.1 Max: 4.7
Current: 0.2
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.22
GSK's Price/Projected FCF is ranked higher than
56% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. GSK: 2.22 )
Ranked among companies with meaningful Price/Projected FCF only.
GSK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2.22
0.97
21.79
Price/Median PS Value 0.96
GSK's Price/Median PS Value is ranked higher than
68% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. GSK: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
GSK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.16 Max: 3.34
Current: 0.96
0.71
3.34
Earnings Yield (Greenblatt) (%) 2.00
GSK's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. GSK: 2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GSK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 9.35 Max: 15.8
Current: 2
1.4
15.8
Forward Rate of Return (Yacktman) (%) -4.26
GSK's Forward Rate of Return (Yacktman) (%) is ranked lower than
75% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. GSK: -4.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GSK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.3  Med: 12.3 Max: 27.8
Current: -4.26
-5.3
27.8

More Statistics

Revenue (TTM) (Mil) $37,472
EPS (TTM) $ 0.11
Beta1.10
Short Percentage of Float0.31%
52-Week Range $37.36 - 45.58
Shares Outstanding (Mil)2,436.20

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 33,104 34,419 35,139 39,169
EPS ($) 2.41 2.50 2.49 2.81
EPS w/o NRI ($) 2.41 2.50 2.49 2.81
EPS Growth Rate
(3Y to 5Y Estimate)
6.26%
Dividends Per Share ($) 2.02 2.02 2.00 2.02
» More Articles for GSK

Headlines

Articles On GuruFocus.com
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 
Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 
Kahn Brothers Adds to 4 Holdings in 3rd Quarter Nov 02 2016 
Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter Oct 11 2016 
Examine Cognizant's Recent Developments Closely Oct 06 2016 
Novartis Is Surviving Oct 03 2016 
Strong Revenue Points to Gains at GlaxoSmithKline Oct 01 2016 
Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016 
John Rogers' Ariel Global Fund 2nd Quarter Commentary Sep 28 2016 

More From Other Websites
What Smart Money Thinks About GlaxoSmithKline plc (ADR) (GSK) Dec 04 2016
How to Buy GlaxoSmithKline at a 15% Discount Dec 02 2016
GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala Dec 02 2016
Glaxo and Innoviva Get Positive News (GSK, INVA) Dec 02 2016
GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy... Dec 02 2016
GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy... Dec 02 2016
Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
Director/PDMR Shareholding Dec 01 2016
Total Voting Rights Dec 01 2016
GSK biotech asthma drug wins UK approval after extra price cut Nov 30 2016
GSK biotech asthma drug wins UK approval after extra price cut Nov 30 2016
GlaxoSmithKline PLC (ADR) (GSK) Targeting Blockbuster Sales With Shingles Vaccine On EU Approval Nov 30 2016
GlaxoSmithKline Plans Nigeria Health Boost After Drinks Sale Nov 29 2016
Should You Buy 3M Co (MMM)? Nov 29 2016
Injections, implants tested as new weapons to prevent HIV Nov 29 2016
Injections, implants tested as new weapons to prevent HIV Nov 29 2016
[$$] Pharma giants see future of lower healthcare profits Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)